Market Research Industry Reports

Gastritis - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Gastritis - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Pipeline Review, H1 2018, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Gastritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 2 respectively.

Gastritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastritis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Gastritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastritis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastritis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastritis - Overview 6
Gastritis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Gastritis - Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Gastritis - Companies Involved in Therapeutics Development 19
BCWorld Pharm Co Ltd 19
Daewon Pharm Co Ltd 19
Daewoong Pharmaceutical Co Ltd 20
Recce Ltd 20
RedHill Biopharma Ltd 21
Sequella Inc 21
Gastritis - Drug Profiles 22
AK-002 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
BCWPA-001 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
DW-3101 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
DWJ-1366 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
HPi-1 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
netazepide - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ondansetron hydrochloride CR - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
RECCE-327 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SQ-109 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Gastritis - Dormant Projects 46
Gastritis - Product Development Milestones 47
Featured News & Press Releases 47
Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 47
Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 47
Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 48
Mar 02, 2015: Positive Bioavailability Studies of RedHills BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 49
Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 50
Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List Of Tables

List of Tables
Number of Products under Development for Gastritis, H1 2018 7
Number of Products under Development by Companies, H1 2018 9
Products under Development by Companies, H1 2018 10
Number of Products by Stage and Target, H1 2018 12
Number of Products by Stage and Mechanism of Action, H1 2018 14
Number of Products by Stage and Route of Administration, H1 2018 16
Number of Products by Stage and Molecule Type, H1 2018 18
Gastritis - Pipeline by BCWorld Pharm Co Ltd, H1 2018 19
Gastritis - Pipeline by Daewon Pharm Co Ltd, H1 2018 20
Gastritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018 20
Gastritis - Pipeline by Recce Ltd, H1 2018 20
Gastritis - Pipeline by RedHill Biopharma Ltd, H1 2018 21
Gastritis - Pipeline by Sequella Inc, H1 2018 21
Gastritis - Dormant Projects, H1 2018 46

List Of Figures

List of Figures
Number of Products under Development for Gastritis, H1 2018 7
Number of Products under Development by Companies, H1 2018 8
Number of Products by Targets, H1 2018 11
Number of Products by Stage and Targets, H1 2018 11
Number of Products by Mechanism of Actions, H1 2018 13
Number of Products by Stage and Mechanism of Actions, H1 2018 13
Number of Products by Routes of Administration, H1 2018 15
Number of Products by Stage and Routes of Administration, H1 2018 15
Number of Products by Molecule Types, H1 2018 17
Number of Products by Stage and Molecule Types, H1 2018 17

Gastritis - Pipeline Review, H1 2018

Gastritis - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Pipeline Review, H1 2018, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.Gastritis

USD 2000View Report

Gastritis - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsights Gastritis - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Gastritis epidemiology and market outlook for the 7MM.Markets Covered United

USD 6250View Report

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018According to the recently published report Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or

USD 3500View Report

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : May 2018
No. of Pages :53
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube